Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | G6PD | P11413 | 1/20 | 0.37 |
| ▸ | IDE | P14735 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2896336 | 1.00 | PTGS2 (0.38) | PTGS2LMNAGAASLC6A9ALDH1A1 | |
| SCHEMBL4369013 | 0.81 | DGAT1 (0.53) | PTGS2LMNASLC6A9BRD4 | |
| SCHEMBL2893503 | 0.81 | LMNA (0.49) | LMNAGAAALDH1A1 | |
| SCHEMBL20136501 | 0.81 | LMNA (0.41) | PTGS2LMNASLC6A9ALDH1A1ENPP2 | |
| SCHEMBL2893505 | 0.81 | LMNA (0.49) | LMNAGAAALDH1A1 | |
| SCHEMBL20136500 | 0.81 | LMNA (0.41) | PTGS2LMNASLC6A9ALDH1A1ENPP2 | |
| SCHEMBL20148140 | 0.81 | LMNA (0.41) | PTGS2LMNASLC6A9ALDH1A1ENPP2 | |
| SCHEMBL4412567 | 0.76 | LMNA (0.59) | PTGS2LMNASLC6A9ALDH1A1ENPP2 | |
| SCHEMBL1061020 | 0.75 | PTGS2 (0.41) | PTGS2LMNASLC6A9ENPP2KIF11 | |
| SCHEMBL8114283 | 0.75 | LMNA (0.49) | PTGS2LMNASLC6A9ALDH1A1ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687492-B2 | 1,2,4-Oxadiazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687492-B2 | 1,2,4-Oxadiazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20090325924-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090325924-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20080021009-A1 | 1,2,4-Oxadiazole Derivatives as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK SHARP & DOHME LLC | 2008-01-24 | — | — | US | disclosed |
| US-20080021009-A1 | 1,2,4-Oxadiazole Derivatives as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK SHARP & DOHME LLC | 2008-01-24 | — | — | US | disclosed |
| EP-1756074-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co., Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| WO-2007003960-A1 | GPCR AGONISTS | PROSIDION LIMITED (GB) | 2007-01-11 | — | — | WO | disclosed |
| WO-2005108382-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325924-A1 | GPCR Agonists | GPR119, GCGR, GPR27 | PTGS2 1870/4885LMNA 4210/4885GAA 1245/4885 |
| US-20080021009-A1 | 1,2,4-Oxadiazole Derivatives as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | DPP4, DPP3, DPP7 | PTGS2 759/4885LMNA 4064/4885GAA 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.